Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma

This study has suspended participant recruitment.
(Enrollment was stopped based on the Data Monitoring Committee's recommendation.)
Sponsor:
Information provided by (Responsible Party):
Inovio Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00198315
First received: September 12, 2005
Last updated: October 8, 2013
Last verified: October 2013

September 12, 2005
October 8, 2013
June 2004
June 2007   (final data collection date for primary outcome measure)
Function status at 4 months using the performance status scale for head and neck cancer (PSSHN) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck (EORTC-QLC-H&N35) [ Time Frame: 4 Months ] [ Designated as safety issue: No ]
Function status at 4 months using head and neck performance scale PSSHN and Quality of Life scale EORTC-QLC-H&N35
Complete list of historical versions of study NCT00198315 on ClinicalTrials.gov Archive Site
  • Local tumor recurrence, disease free survival and overall survival rates through 2 years after bleomycin-EPT or surgery treatment [ Time Frame: 4 Months ] [ Designated as safety issue: Yes ]
  • Safety through 6 months after the study treatment [ Time Frame: 6 Months ] [ Designated as safety issue: Yes ]
  • Durability of function status outcomes at 8 months after bleomycin-EPT or surgery treatment [ Time Frame: 8 Months ] [ Designated as safety issue: No ]
  • Pharmacoeconomic parameters through 8 months after bleomycin-EPT or surgery treatment [ Time Frame: 8 Months ] [ Designated as safety issue: No ]
  • Bleomycin systemic absorption and plasma pharmacokinetics following intratracheal (IT) bleomycin-EPT administration [ Time Frame: 96 Hours ] [ Designated as safety issue: Yes ]
  • Local tumor recurrence, disease free survival and overall survival rates through 2 years after bleomycin-EPT or surgery treatment.
  • Safety through 6 months after the study treatment.
  • Durability of function status outcomes at 8 months after bleomycin-EPT or surgery treatment.
  • Pharmacoeconomic parameters through 8 months after bleomycin-EPT or surgery treatment.
  • Bleomycin systemic absorption and plasma pharmacokinetics following IT bleomycin-EPT administration.
Not Provided
Not Provided
 
Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma
A Randomized Trial Comparing Preservation of Function Status After Either Medpulser Electroporation With Intratumoral Bleomycin Therapy or Surgery in Patients With Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Anterior Oral Cavity, Soft Palate, or Tonsil That Have Failed Primary Curative Therapy

The purpose of the study is to evaluate Medpulser electroporation (EPT) with bleomycin with regard to local tumor recurrence, disease-free survival, and overall survival rates versus surgery in recurrent or secondary primary squamous cell carcinoma (SCC) of the anterior oral cavity, soft palate, or tonsil.

Recurrent tumors in head and neck squamous cell carcinoma usually have a poor prognosis. In patients suitable for salvage surgery of their recurrent disease, the success rate for local control has been reported to be 40-50%. The surgical treatment of H&N SCC frequently results in significant loss of organ function (e.g., inability to swallow, speak, etc.) and/or permanent disfigurement. There is a compelling and unmet medical need for a local therapy that destroys tumors while preserving function status and appearance in patients with primary, recurrent, or metastatic H&N SCC.

Comparison: To compare function status at 4 months after treatment with bleomycin-EPT or surgery in patients with locally recurrent or second primary SCC of the anterior oral cavity, soft palate, or tonsil that have failed primary curative therapy and in whom surgical resection is seen as an option for disease control.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Head and Neck Cancer
  • Device: Medpulser electroporation with Bleomycin
    Patients receive electroporation with injection of bleomycin sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area.
  • Procedure: Tumor surgical excision
    Patients have their tumor surgically removed.
  • Active Comparator: Surgery Control
    Patients will receive standard of care surgical removal of their tumor.
    Intervention: Procedure: Tumor surgical excision
  • Experimental: MedPulser EPT
    Patients who are eligible for surgical excision will receive MedPulser electroporation with injection of bleomycin sulfate into the tumor treatment area.
    Intervention: Device: Medpulser electroporation with Bleomycin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Suspended
200
June 2007
June 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. The presence of SCC of the anterior oral cavity, soft palate or tonsil must be confirmed by histological examination of a tissue sample (e.g., biopsy) obtained within 1 month of the patient receiving the study treatment.
  2. Recurrent or second primary disease in patients where surgical resection is seen as an option for disease control.
  3. The length of the longest diameter of the study lesion must be < 5 cm and the calculated treatment volume must be < 60.0 cm3 (tumor volume plus a 0.5 cm margin around the tumor) for the study lesion [where treatment volume = 0.5 (A+1) (B+1)2 and where A = length of the longest diameter (cm), B = the next longest diameter perpendicular to "A" (cm)].
  4. Tumor burden must be completely encompassed by surgery or bleomycin-EPT.
  5. Age: 18 years or older.
  6. Men and women of childbearing potential must use physician approved contraceptive methods for 7 days following bleomycin-EPT.
  7. Hematopoietic status:

    • Absolute neutrophil count (ANC) > 1000/uL
    • Platelets > 75,000/mm3
    • Prothrombin time:international normalized ratio (PT:INR) ? 1.5 (correctable with vitamin K injection)
  8. Blood chemistry status:

    • Transaminases < 3 times upper limit of normal
    • Total bilirubin < 2.5 mg/dL
    • Creatinine < 2.5 mg/dL
  9. A written Informed Consent form must be signed prior to the patient receiving any study procedures or treatments.

Exclusion Criteria:

  1. Patients with tumors suspected of involving a 50% or greater encasement of a blood vessel as measured by magnetic resonance imaging (MRI) or computed tomography (CT) scan.
  2. Patients with tumors having bone invasion.
  3. Patients with any metallic implants in the treatment field.
  4. Patients with hypersensitivity to bleomycin.
  5. Patients who have received or will exceed a total lifetime dose of bleomycin greater than 400 units.
  6. Patients deemed unsuitable for general anesthesia.
  7. Patients with a significant history of emphysema or pulmonary fibrosis.
  8. Patients with indwelling cardiac pacemakers who cannot tolerate a period with pacemaker turned off.
  9. Patients with a history of uncontrolled cardiac arrhythmia.
  10. Women who are pregnant, or are nursing. Women of childbearing potential must have a negative beta-human chorionic gonadotropin (beta-HCG) test within 7 days of study treatment.
  11. Radiation therapy to the treatment area within 8 weeks of study treatment.
  12. Chemotherapy or other cancer therapy (e.g., surgery, cryotherapy, etc.) to the treatment area within 4 weeks of study treatment.
  13. Patients participating in a clinical study for an investigational drug or device within 4 weeks prior to the study treatment.
  14. Patients previously randomized to this study.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00198315
HNBE-03-01, HNBE-03-01
Yes
Inovio Pharmaceuticals
Inovio Pharmaceuticals
Not Provided
Study Chair: Paul Goldfarb, MD Inovio Pharmaceuticals
Inovio Pharmaceuticals
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP